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Aims Patients with chronic heart failure (CHF) show impaired health-related quality of life (HRQoL), an important target
for therapeutic intervention. Impaired iron homeostasis may be one mechanism underlying the poor physical condi-
tion of CHF patients. This detailed subanalysis of the previously published FAIR-HF study evaluated baseline HRQoL
in iron-deficient patients with CHF and the effect of intravenous ferric carboxymaltose (FCM) on HRQoL.
Methods
and results
FAIR-HF randomized 459 patients with reduced left ventricular ejection fraction and iron deficiency, with or without
anaemia, to FCM or placebo (2:1). Health-related quality of life was assessed at baseline and after 4, 12, and 24 weeks
of therapy using the generic EQ-5D questionnaire and disease-specific Kansas City Cardiomyopathy Questionnaire
(KCCQ). Baseline mean Visual Analogue Scale (VAS) score was 54.3+16.4 and KCCQ overall summary score was
52.4+ 18.8. Ferric carboxymaltose significantly improved VAS and KCCQ (mean differences from baseline in KCCQ
overall, clinical and total symptom scores, P, 0.001 vs. placebo) at all time points. At Week 24, significant improve-
ment vs. placebo was observed in four of the five EQ-5D dimensions: mobility (P ¼ 0.004), self-care (P, 0.001),
pain/discomfort (P ¼ 0.006), anxiety/depression (P ¼ 0.012), and usual activity (P ¼ 0.035). Ferric carboxymaltose
improved all KCCQ domain mean scores from Week 4 onward (P ≤ 0.05), except for self-efficacy and social
limitation. Effects were present in both anaemic and non-anaemic patients.
Conclusions HRQoL is impaired in iron-deficient patients with CHF. Intravenous FCM significantly improved HRQoL after 4
weeks, and throughout the remaining study period. The positive effects of FCM were independent of anaemia status.
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Introduction
Patients with chronic heart failure (CHF) suffer from a marked
impairment of health-related quality of life (HRQoL) compared
with the normal population and patients with other chronic condi-
tions.1–3 Among the factors associated with a reduced HRQoL, dys-
pnoea and fatigue are major symptoms of CHF that persist in many
patients despite optimal drug and device management.4 Limited
options for treatment of underlying CHF pathology have caused
the focus of therapeutic attention to shift towards patient-centred
outcomes such as HRQoL, particularly in those already receiving
evidence-based therapy and even more so in those with limited
life expectancy.5,6 Currently, an improvement in patient-reported
outcomes is considered one of the main goals of comprehensive
CHF management.7–9 Moreover, despite their benefits in survival,
some of the usual therapies used in CHF, such as beta-blockers,
have failed to prove a positive effect in terms of HRQoL.10
Iron plays a vital role in energy-dependent physiological pro-
cesses such as erythropoiesis and oxidative phosphorylation,11,12
and iron deficiency (ID) may be a frequent and significant
comorbidity in CHF.13 Beyond anaemia, ID is a determinant of
fatigue and impaired exercise capacity in otherwise healthy popu-
lations.14,15 In this context, there is recent evidence that ID in CHF
patients is also associated with impaired exercise capacity, worse
functional New York Heart Association (NYHA) class, and
poorer outcomes, although this latter observation remains contro-
versial.13,16,17 Iron deficiency is, therefore, a potential treatment
target to improve HRQoL in CHF patients.11,18
Beyond small studies, there is little information about HRQoL
in iron-deficient CHF patients and the potential benefits of iron
repletion therapy. The FAIR-HF study (Ferric carboxymaltose
Assessment in patients with IRon deficiency and chronic Heart
Failure) was designed to determine the effects of intravenous
(i.v.) ferric carboxymaltose (FCM) in iron-deficient CHF patients.18
Ferric carboxymaltose was well tolerated and significantly
improved CHF symptoms, exercise capacity, and HRQoL.19 In
the current study, we undertook a detailed subanalysis of
FAIR-HF to gain specific insight into the effects of FCM on different
domains of HRQoL in iron-deficient CHF patients.
Methods
Study design
The rationale and design of the FAIR-HF study has been previously
published.18 Briefly, FAIR-HF was a randomized, double-blind, placebo-
controlled, 24-week study of the effects of i.v. FCM [Ferinjectw, Vifor
(International), Inc., St Gallen, Switzerland] in iron-deficient patients
with CHF due to systolic dysfunction, with or without anaemia. The
main study inclusion criteria were NYHA class II/III, the left ventricular
ejection fraction (LVEF) ≤40% (NYHA II) or ≤45% (NYHA III),
haemoglobin (Hb) levels between 9.5 and 13.5 g/dL, and ID [defined
as serum ferritin ,100 mg/L, or as serum ferritin ,300 mg/L if trans-
ferrin saturation (TSAT) was ,20%].
After 24 weeks of therapy, the patients in the FCM group experi-
enced a significant improvement in the Patient Global Assessment
(PGA) score, NYHA class (co-primary endpoints) and 6-minute
walking test distance (secondary endpoint) compared with patients
receiving placebo.19
Health-related quality of life measurements
Two standard instruments were used: the disease-specific Kansas City
Cardiomyopathy Questionnaire (KCCQ) and the generic EuroQoL
EQ-5D questionnaire.
The KCCQ20 is a disease-specific measure of HRQoL for heart
failure comprising seven domains (physical limitation, symptom stabil-
ity, symptom burden, symptom frequency, self-efficacy, quality of life,
and social limitation) and three summary scores [total symptom
score (TSS, comprising symptom frequency and symptom burden),
overall summary score (OSS, comprising physical limitation, TSS,
quality of life and social limitation), and clinical summary score (CSS,
comprising physical limitation, TSS)]. Scores ranged between 0 and
100, where 100 is the best possible HRQoL status. A five-unit
change in the OSS was defined as the minimally noticeable clinical
difference in response to treatment.21
The EQ-5D instrument9 is a generic measure of HRQoL, comprising
a Visual Analogue Scale (VAS) for self-rating of general health (a score
of 100 is the best possible general health status) and five domains
evaluating mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression. In this instrument, 1 is the best possible general
health status in each case; the dimensions may also be expressed as
percentage of patients rating 1–3 (best to worst health status) or per-
centage of patients with ‘any’ complaint (scoring 2 or 3 in each
domain). The results for the five domains can be converted into a
single summary index score by weighting the individual values and
deducting the weighted values from 1, the value for full health (i.e.
state 11111). In this study, the index was multiplied by 100. The min-
imally important difference (MID) in the EQ-5D index score is defined
as the smallest change in the index score that can be regarded as
important and meaningful for health professionals, patients, and
other stakeholders. Based on data from 11 patient groups in eight lon-
gitudinal studies, the MID has been estimated to be 0.074 (7.4%).9,22
During the FAIR-HF study, the EQ-5D questionnaire and the KCCQ
were self-administered at baseline, and at Weeks 4, 12, and 24, before
any other assessment or procedure.
Statistical analysis
Data analysis was performed using the full analysis set based on the
intention-to-treat principle for each assigned study group. We used
a two-tailed significance level of a ¼ 0.05 for all assessments. We
present data at baseline as mean+ SD or number (per cent).
Health-related quality of life data are presented as mean+ SEM.
For the continuous variables, changes from the baseline value and
values at Weeks 4, 12, and 24 were compared between the FCM
group and the placebo group by means of repeated measures analysis
of covariance. The statistical model included treatment group, visit
and their interaction as categorical variables and baseline value as a
continuous covariate. An unstructured covariance matrix was used.
For categorical endpoints, differences in the distribution of the two
study groups were tested by means of ordered polytomous regression
for repeated measures. The same explanatory variables were used as
in the analyses of continuous endpoints, and an unstructured covari-
ance matrix was used.
Missing HRQoL data at each time point were defined as the follow-
ing: no EQ-5D VAS score, no EQ-5D index score, or no KCCQ OSS.
Missing data for patients known to be alive and not hospitalized at the
time point being analysed were imputed using the ‘last observation
carried forward’ method, for which at least one previous follow-up
value was required. If no preceding HRQoL values were available,
the patient was excluded in that analysis. For hospitalized patients
unable to complete the questionnaires, or if the patient had died
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between the last time point and the planned time point, the worst
reply was used for the imputation (i.e 1 for the KCCQ individual
domains, 3 for the EQ-5D sub-questions, and 0 for the EQ-5D VAS
score).
The effects of baseline characteristics on baseline HRQoL were
assessed by means of analysis of covariance models. Using simple
backward elimination, non-significant variables (P. 0.10) were
removed from the model one at a time. Tests for interaction (e.g.
treatment-by-baseline NYHA) were performed by analysing the data
by visit and adding the interaction term to the statistical models. All
analyses were conducted with the SAS software, version 9.1 (SAS
Institute, Inc., Cary, NC, USA: 2000–2004).
Results
The screening and inclusion process for eligible patients, baseline
characteristics, and primary and secondary endpoint results have
been published.19 Here, we present otherwise unpublished specific
HRQoL analyses, and only show previously published data, appro-
priately cited, when they are required to understand the current
analyses.
The two treatment groups were well matched for patient demo-
graphic, laboratory parameters, and treatment characteristics. At
the start of the study, the mean (+SD) age was 67.8+10.3 and
67.4+ 11.1 years in the FCM and placebo groups, respectively.
In the FCM group, 52.3% of patients were women, compared
with 54.8% in the placebo group.19 All patients were in either
NYHA class II or II, with 83% in the FCM group and 81% in the
placebo group in NYHA class III.19 The FCM and placebo
groups, respectively, were well matched for mean (+SD) %
LVEF (32.5+5 and 33+ 6) and the Hb level (11.9+1.3 and
11.9+ 1.4 g/dL).19 In both groups, 48% of patients were anaemic
(Hb ≤12 g/dL).19
Health-related quality of life data were available for over 90 per
cent of patients at all time points. The two groups had similar
HRQoL scores at baseline as measured by EQ-5D VAS score,
index score, and domains, and by the KCCQ summary scores
and domain scores (Table 1).
Baseline health-related quality of life
in chronic heart failure patients
At baseline, HRQoL was lower in patients with anaemia compared
with non-anaemic patients (Table 2). Likewise, symptom severity
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Table 1 Baseline health-related quality of life
FCM
(n5 304)
Placebo
(n5 155)
HRQoL: EQ-5D
Visual analogue scale
Missing data, n (%) 9 (3) 3 (2)
Mean+ SEM 54+1 54+1
Index score (×100)
Missing data, n (%) 6 (2) 1 (1)
Mean+ SEM 68+1 69+1
Patients reporting any problemby domain
Mobility, n (%) 245 (81) 131 (85)
Self-care, n (%) 146 (49) 79 (51)
Usual activity, n (%) 232 (77) 124 (81)
Pain/discomfort, n (%) 228 (76) 117 (75)
Anxiety/depression, n (%) 194 (65) 97 (63)
HRQoL: KCCQ
Missing data, n (%) 7 (2) 4 (3)
Overall summary score, mean+ SEM 52+1 53+1
Clinical summary score, mean+ SEM 55+1 55+1
Total symptom score, mean+ SEM 59+1 59+2
Physical limitation, mean+ SEM 52+1 52+2
Symptom burden, mean+ SEM 59+1 60+1
Symptom frequency, mean+ SEM 59+1 58+2
Symptom stability, mean+ SEM 54+1 53+1
Self-efficacy, mean+ SEM 64+1 63+2
Quality of life, mean+ SEM 47+1 48+2
Social limitation, mean+ SEM 51+2 51+2
Visual Analogue Scale and Kansas City Cardiomyopathy Questionnaire overall
summary score data were previously published, and are included here for
context.16
KCCQ, Kansas City Cardiomyopathy Questionnaire.
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Table 2 Differences in baseline health-related quality of life according to anaemia status and NYHA class
Anaemic
(n5 220)
Non-anaemic
(n 5 221)
P (anaemic vs.
non-anaemic)
NYHA III
(n 5 377)
NYHA II
(n 5 82)
P (NYHA III
vs. NYHA II)
HRQoL: EQ-5D
Visual Analogue Scale, mean+ SEM 53.0+1.1 55.6+1.1 0.093 52.5+0.8 62.4+1.9 ,0.001
Index score (×100), mean+ SEM) 66.2+1.0 70.7+1.1 0.002 66.7+0.8 76.5+1.6 ,0.001
HRQoL: KCCQ
Overall summary score, mean+ SEM 49.3+1.2 55.7+1.3 ,0.001 49.4+0.9 66.8+1.9 ,0.001
Clinical summary score, mean+ SEM 52.4+1.2 58.6+1.3 ,0.001 52.0+0.9 71.8+1.8 ,0.001
Total symptom score, mean+ SEM 56.3+1.3 61.6+1.4 ,0.005 55.5+1.0 75.2+1.9 ,0.001
NYHA, New York Heart Association; EQ-5D, Euro QoL 5 Dimensions; KCCQ, Kansas City Cardiomyopathy Questionnaire.
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Table 3 Absolute and percentage change from baseline in generic quality of life measured using the EQ-5D instrument
Week 4 Week 12 Week 24
FCM (n 5 304) Placebo (n 5 155) FCM (n 5 304) Placebo (n 5 155) FCM (n 5 304) Placebo (n 5 155)
EQ-5D Visual Analogue Scale
Missing data, n (%) 30 (9.9) 15 (9.7) 21 (6.9) 10 (6.5) 19 (6.3) 9 (5.8)
Mean+ SEM (% change from baseline) 6.0+0.7 (17.4+2.1)*** 0.8+1.3 (4.8+2.8) 7.9+0.8 (21.4+2.3)*** 2.4+1.5 (7.9+3.2) 9.1+1.0 (24.6+2.7)*** 3.4+1.6 (9.9+3.3)
EQ-5D index score
Missing data, n (%) 29 (9.5) 13 (8.4) 17 (5.6) 8 (5.2) 16 (5.3) 7 (4.5)
Mean+ SEM, ×100 (% change from baseline) 5.9+0.8 (12.6+1.8)*** 0.6+1.5 (5.1+2.8) 6.9+1.0 (15.1+2.2)*** 21.6+1.7 (0.5+3.3) 6.6+1.2 (14.4+2.5)*** 21.0+1.8 (1.5+3.2)
Mobility, n (%) reporting improvement 46 (16.5) 15 (10.4) 55 (19.0)*** 9 (6.1) 59 (20.3)** 17 (11.4)
Self-care, n (%) reporting improvement 43 (15.5)** 14 (9.8) 54 (18.8)*** 17 (11.6) 61 (21.1)*** 14 (9.5)
Usual activity, n (%) reporting improvement 53 (18.9)* 18 (12.7) 62 (21.4) 23 (15.6) 70 (24.1)* 23 (15.5)
Pain/discomfort, n (%) reporting improvement 57 (20.3)* 21 (14.7) 77 (26.6)*** 22 (14.9) 82 (28.2)** 25 (16.8)
Anxiety/depression, n (%) reporting improvement 68 (24.3) 30 (21.0) 84 (29.1)* 33 (22.3) 94 (32.4)* 37 (24.8)
Visual Analogue Scale data were previously published, and are included here for context.16
*P, 0.05; **P, 0.01; ***P, 0.001 for ferric carboxymaltose vs. placebo.
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Table 4 Absolute and percentage change from baseline in heart-failure-specific quality of life measured using the Kansas City Cardiomyopathy Questionnaire
Week 4 Week 12 Week 24
FCM (n 5 304) Placebo (n5 155) FCM (n 5 304) Placebo (n 5 155) FCM (n 5 304) Placebo (n 5 155)
HRQoL: KCCQ
Missing data, n (%) 27 (8.9) 15 (9.7) 18 (5.9) 11 (7.1) 18 (5.9) 10 (6.5)
Overall summary score, mean+ SEM (% change from baseline) 9.4+ 0.9 (33.6+ 5.2)*** 3.5+ 1.2 (10.6+ 3.3) 12.2+ 1.1 (41.9+ 5.8)*** 4.6+ 1.4 (16.1+ 5.4) 12.8+ 1.3 (43.9+ 6.1)*** 6.2+ 1.5 (21.5+ 6.7)
Clinical summary score, mean+ SEM (% change from baseline) 9.3+ 0.9 (29.9+ 4.3)*** 2.7+ 1.2 (7.0+ 2.5) 11.6+ 1.1 (36.2+ 4.7)*** 3.3+ 1.4 (9.4+ 3.5) 11.4+ 1.3 (36.8+ 4.9)*** 4.2+ 1.5 (12.6+ 3.7)
Total symptom score, mean+ SEM (% change from baseline) 10.4+ 1.0 (34.1+ 5.1)*** 3.1+ 1.2 (7.5+ 2.6) 12.7+ 1.2 (38.0+ 4.4)*** 3.3+ 1.5 (8.2+ 3.3) 12.0+ 1.3 (36.3+ 4.5)*** 3.9+ 1.6 (11.5+ 3.5)
Physical limitation, mean+ SEM (% change from baseline) 8.2+ 1.1 (31.7+ 4.7)*** 2.3+ 1.4 (9.8+ 3.7) 10.5+ 1.3 (39.5+ 5.9)*** 3.3+ 1.6 (11.8+ 4.2) 10.7+ 1.5 (45.5+ 7.1)** 4.5+ 1.8 (13.5+ 4.1)
Symptom frequency, mean+ SEM (% change from baseline) 10.1+ 1.1 (40.9+ 8.8)*** 4.1+ 1.4 (12.2+ 3.4) 12.0+ 1.2 (44.2+ 7.9)*** 3.2+ 1.5 (10.2+ 3.9) 11.5+ 1.4 (41.4+ 8.1)*** 4.6+ 1.7 (17.6+ 4.6)
Symptom stability, mean+ SEM (% change from baseline) 12.7+ 1.4 (32.3+ 3.3)*** 1.6+ 1.9 (8.9+ 4.4) 14.2+ 1.7 (37.6+ 3.9)*** 1.7+ 2.1 (11.6+ 5.4) 13.2+ 1.7 (33.8+ 3.7)*** 4.5+ 2.1 (17.0+ 5.4)
Symptom burden, mean+ SEM (% change from baseline) 10.8+ 1.1 (35.2+ 5.2)*** 2.1+ 1.3 (6.1+ 2.7) 13.3+ 1.2 (40.8+ 5.1)*** 3.3+1.6 (9.2+ 3.6) 12.5+ 1.4 (39.0+ 5.1)*** 3.3+ 1.7 (10.2+ 3.6)
Self-efficacy, mean+ SEM (% change from baseline) 6.9+ 1.3 (23.5+ 4.3) 5.7+ 1.9 (23.0+ 7.4) 8.9+ 1.3 (28.8+ 4.8)* 4.3+ 2.4 (21.3+ 7.4) 9.7+ 1.5 (30.0+ 5.0) 6.0+ 2.4 (26.3+ 7.8)
Quality of life, mean+ SEM (% change from baseline) 8.7+ 1.1 (36.8+ 5.8)** 3.6+ 1.6 (19.8+ 7.1) 13.3+ 1.3 (54.9+ 7.0)*** 4.5+ 1.6 (21.7+ 6.9) 14.8+ 1.4 (59.1+ 7.3)*** 6.8+ 1.8 (31.8+ 8.8)
Social limitation, mean+ SEM (% change from baseline) 10.2+ 1.4 (46.6+ 8.5)** 4.1+ 1.7 (15.0+ 5.3) 12.1+ 1.6 (55.2+ 11.0)* 7.2+ 2.1 (25.4+ 7.1) 13.1+ 1.7 (54.4+ 9.7) 8.5+ 2.2 (27.5+ 6.9)
KCCQ overall summary score data were previously published, and are included here for context.16
*P, 0.05; **P, 0.01; ***P, 0.001 for ferric carboxymaltose vs. placebo.
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(NYHA class III vs. II) was associated with incrementally worse
HRQoL (Table 2).
Age at baseline, gender, baseline NYHA, ischaemic aetiology of
CHF, baseline serum iron, serum ferritin, TSAT, and Hb were asso-
ciated with baseline QoL scores in the univariate analyses. We
fitted an analysis of covariance model with a range of these
possible predictors. Through backward elimination, non-significant
variables were removed. In the final model, baseline NYHA
class (P, 0.001), baseline Hb (P ¼ 0.02), and baseline TSAT
(P ¼ 0.04) were associated with HRQoL (KCCQ OSS).
Effect of intravenous ferric
carboxymaltose on health-related
quality of life
As previously published, FCM significantly improved EQ-5D VAS
and KCCQ OSS.19 In our analysis, we found that FCM also
improved EQ-5D index scores, and other summary scores of the
KCCQ, such as CSS and TSS consistently after 4 weeks of treat-
ment initiation. These effects were maintained or increased
throughout the study (FCM P, 0.001 vs. placebo at each time
point, Tables 3 and 4). The changes from baseline in EQ-5D VAS
and index scores ranged on average between 13 and 25% through-
out the study, compared with ,10% among the placebo group
(Table 3).
There was a greater improvement in the percentage of patients
reporting any complaint in each EQ-5D domain in the FCM group
compared with the placebo group (Table 3). Throughout the study,
significantly more (P, 0.02) patients reported an MID in the FCM
group (37–45%) compared with the placebo group (22–29%;
Figure 1). In addition to overall improvement, FCM treatment
was associated with lower rates of deterioration in HRQoL
reported throughout the study (Figure 2).
The proportion of patients experiencing a clinically significant
five-point change in KCCQ OSS at Week 24 was significantly
higher in the FCM group compared with placebo patients (61 vs.
51%; P ¼ 0.04). The individual percentage changes in KCCQ CSS
and TSS (Table 4) were at least three times greater among patients
receiving FCM (30–37%) than those receiving placebo (7.0–
12.6%), and OSS changes were two or three times greater
among the iron-treated group. Among the individual domains,
the greatest differences in percentage change between FCM and
placebo groups were seen in symptom-related domains, where
improvements were mostly three or four times greater in the
FCM group than the placebo group. Likewise, iron treatment
resulted in an approximately three-fold improvement in physical
limitation compared with placebo. However, there were no
major differences between groups in self-efficacy scores.
As shown in Figures 3 and 4, the effects of FCM on HRQoL as
measured by KCCQ were independent of a range of pre-specified
variables, including baseline anaemia, renal function, age, CHF aeti-
ology, and diabetes. The efficacy of FCM at Week 24 appeared to
be affected by baseline CHF severity as indicated by NYHA class
(Figure 3), an effect also observed in the KCCQ CSS (PInteraction¼
0.04), TSS (PInteraction¼ 0.03), QoL score (PInteraction¼ 0.01), and
symptom burden score (PInteraction¼ 0.02).
Although anaemia was associated with lower baseline HRQoL in
patients with ID compared with ID without anaemia, there were
no significant differences between FCM treatment effects observed
in anaemic and non-anaemic patients at the end of the study (after
adjustment for baseline differences) for the KCCQ OSS (Figure 3).
Values at Week 24 in the FCM group [adjusted for baseline (+
SEM) in the anaemic and non-anaemic subgroups, respectively]
were: EQ-5D index score 74.7+ 1.6 vs. 75.7+1.6 (P ¼ 0.66);
EQ-5D VAS 63.1+ 1.3 vs. 63.8+ 1.3 (P ¼ 0.74); KCCQ OSS
66.1+ 1.6 vs. 64.9+1.6 (P ¼ 0.61). The absence of differences
in treatment effects according to anaemia status was also observed
for other relevant domains and summary scores of the KCCQ that
specifically capture information about symptoms and physical
limitation such as KCCQ CSS, and about HRQoL, such as the
KCCQ QoL domain (Figure 4).
Discussion
The primary analysis of the FAIR-HF study showed that FCM treat-
ment improved overall measures of HRQoL (EQ-5D VAS and
Figure 1 Percentage of iron-deficient chronic heart failure patients treated with ferric carboxymaltose or placebo reporting at least a min-
imally important difference in EQ-5D index score at each study time point [minimally important difference is the smallest index score change
meaningful for health professionals, patients and other stakeholders, and is 0.074 (7.4%) for the EQ-5D index score].1,22
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index scores, and KCCQ OSS) in patients with CHF and ID after 4
weeks of treatment,19 confirming the findings of several smaller
studies.23–25 Here, we report detailed HRQoL data for baseline
status and the impact of comorbidities on the efficacy of FCM
treatment.
As expected for patients with CHF, cross-study comparisons
revealed a markedly reduced baseline HRQoL in the FAIR-HF
patients relative to age-matched normal populations.1,26 Health-
related quality of life impairment was strongly related to domains
most influenced by physical limitation, such as mobility and usual
activities, although many patients also reported problems in
pain/discomfort and anxiety/depression domains, highlighting the
multidimensional nature of HRQoL.
The effect of FCM on HRQoL was significant throughout the
study, with more patients reporting clinically meaningful changes
in the FCM treatment arm. Consistent with these findings, the
proportion of patients reporting any problems in the EQ-5D
dimensions was significantly reduced at the end of the study only
in the FCM group, and fewer patients in the FCM group experi-
enced deteriorating HRQoL during the study, which may be
important given the progressive nature of the disease.
The positive effect of FCM in HRQoL was consistent among all
pre-specified subgroups, except for NYHA class. Although this
latter observation may be, in part, attributable to the low sample
size and the apparent improvements seen in the placebo arm
among patients in NYHA class II, it may also suggest less improve-
ment in HRQoL in patients with in a lower NYHA class. New York
Heart Association class II patients have better QoL than patients
in higher classes2 and therefore hypothetically there is less room
for improvement. This interaction between NYHA class and
HRQoL was observed consistently in the specific domains and
the summary scores; however, there was no interaction between
NYHA class and the 6MWT, an objective measure of functional
capacity.19 This apparent discrepancy gives support to the evidence
that the correlation between objective functional capacity and
HRQoL is not perfect and that HRQoL measures may provide
additional information not captured by more conventional ways
of assessing physical limitation in patients with CHF.27
Ferric carboxymaltose was equally effective in anaemic and
non-anaemic patients and the effect was independent of baseline
renal function. In the FCM group, the change was more apparent
in anaemic patients, but this could mostly be accounted for by
their lower baseline HRQoL.
The physiological mechanisms behind the favourable change in
HRQoL due to FCM treatment have not been completely
elucidated. Transferrin saturation, a marker of iron availability
and probably ID at the tissue level,28 was independently asso-
ciated with abnormalities in HRQoL at baseline, and further
work is needed to determine the relevance of this. There is
some evidence that poor iron homeostasis is one of the mechan-
isms underlying exercise intolerance in CHF,13,17,19 partly due to
impaired physical function as a result of ID in skeletal and myo-
cardial muscle cells.14,15 In this context, recent studies have
shown that patients with CHF and anaemia commonly exhibit
tissue ID at the myocyte level.29 Furthermore, treatment with
i.v. iron may have favourable effects in cardiac structure and
remodelling.30 We can therefore hypothesise that ID impairs
physical function and promotes symptoms such as fatigue due
to impaired energy metabolism, a common feature in CHF, as
well as due to abnormal erythropoiesis where anaemia is
present.11,13,17,23 These mechanisms may explain why FCM
administration significantly improved HRQoL in both anaemic
Figure 2 Percentage of iron-deficient chronic heart failure
patients treated with ferric carboxymaltose or placebo reporting
improvement or deterioration in health-related quality of life at
study Week 24 as measured using the Kansas City Cardiomyop-
athy Questionnaire (A) overall summary score, (B) overall clinical
score, and (C ) total symptom score.
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and non-anaemic patients, and why this benefit was seen early
after initiation of the therapy, after just 4 weeks, despite only a
modest increase in the Hb level.
Health-related quality of life instruments capture self-perceived
health and are a useful measure of the efficacy of any therapeutic
intervention from the perspective of the patient and the treating
professional. This is particularly relevant in elderly patients with
CHF, where trading longevity for improvement in physical, emo-
tional and social well-being may be the preference.1,27 Also,
patient-reported outcomes have been found to be independent
predictors of outcome in HF patients; therefore, HRQoL may
give important prognostic information.27,31
There are two main limitations to our subanalysis of the
FAIR-HF study. First, the study was not originally powered for
significant differences in terms of the various HRQoL summary
scores and domains, although the findings are consistent with
the changes observed in the two symptom-based primary end-
points of the FAIR-HF study (PGA and NYHA).19 Second, the
selection criteria could limit the generalization of the results to
the CHF population at large, although the positive effects of
FCM were observed in a wide range of different patient
subgroups.
In our study, i.v. iron treatment was considered to be well tol-
erated.19 However, it must be noted that long-term safety data
for treatment with this drug in the setting of CHF are currently
lacking. Studies evaluating longer periods of treatment, such as
CONFIRM-HF (ClinicalTrials.gov identifier: NCT01453608),32
and evaluation of the effect on mortality and morbidity would be
desirable.
In conclusion, we have shown that iron repletion with FCM over
a 24-week period improves generic and disease-specific measures
of HRQoL in stable, symptomatic, and ambulatory CHF patients
with ID and systolic dysfunction. The beneficial effects of FCM
on patient-centred outcomes were observed 4 weeks after initi-
ation of therapy, and were independent of baseline anaemia
status and renal function. In addition to improvements, we
observed less deterioration in HRQoL in patients treated with
FCM. Further research is required to confirm these findings and
to determine the underlying mechanisms of the efficacy of i.v.
iron in patients with ID and CHF.
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